Active Ingredient(s):Gilteritinib FDA Approved: * November 28, 2018 Pharm Company: *ASTELLAS Category:Cancer
Gilteritinib, sold under the brand name Xospata, is an anti-cancer drug.
It acts as an inhibitor of FLT3, hence it is a tyrosine kinase inhibitor.
It was developed by Astellas Pharma.
In April 2018, Astellas filed a new drug application with the Food and Drug Administration for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia (AML).
In November 2018, the ...
* May have multiple approval dates, manufacturers, or labelers.